Study Says Only Half Of Chinese With HIV/AIDS Have Drug Access
This article was originally published in PharmAsia News
Researchers in China have concluded that half of the nation's 700,000 HIV/AIDS patients have ceased drug treatments, most because they no longer have access to the medicines. Research carried out by China's CDC said the results are consistent with other reports of access in low- and middle-income countries. Under a government program launched in 2002, patients were to have access to drugs for free, but that plan failed to treat half the eligible group through 2008. The primary drugs used are GlaxoSmithKline's Retrovir (zidovudine) andEpivir (lamivudine), and Boehringer Ingelheim's Viramune (nevirapine). (Click here for more
You may also be interested in...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Drawing on the company’s Latin name, Viatris – the proposed combination of Mylan and Upjohn – has unveiled a logo and branding “capturing the company’s commitment to access, leadership and partnership.”
Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.